生物活性 | |||
---|---|---|---|
描述 | In parallel research, Hemin and PGJ2 serve as potent inducers of HMOX expression and activity after 4 and 12 hours, respectively. Particularly, Hemin at 30 μM significantly inhibits cell proliferation in various cancer cell lines (PA-TU-8902, BxPC-3, and MiaPaCa-2) in a dose-dependent manner after 48 hours, with proliferation rates dropping to 62±5%, 51±3%, and 38±8% respectively, and with statistical significance (p<0.0001) across all comparisons. Additionally, Hemin is shown to enhance the anti-proliferative effects of statins, as evidenced by further decreased cell proliferation upon 48 hours of co-treatment[1]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01817530 | Heavy Uterine Bleeding ... 展开 >> Uterine Fibroids 收起 << | Phase 2 | Completed | - | - |
NCT03086681 | Cervical Carcinoma | Phase 3 | Not yet recruiting | February 2020 | China, Guangxi ... 展开 >> First Affiliated Hospital of Guangxi Medical University Not yet recruiting Nanning, Guangxi, China, 530021 Contact: Yong Zhang, M.D. 0086-13607884001 zhangyonggx@163.com Contact: Fang Wu, M.D. Sub-Investigator: Jian Li, M.D. Sub-Investigator: Hemin Lu, M.D. Sub-Investigator: Haixin Huang, Master Sub-Investigator: Zhanxiong Luo, Master Sub-Investigator: Meilian Liu, Master Sub-Investigator: Gaojuan Lin, Master Sub-Investigator: Sihui Liao, bachelor Sub-Investigator: Hongqian Wang, bachelor 收起 << |
NCT00307801 | Metrorrhagia | Phase 3 | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.53mL 0.31mL 0.15mL |
7.67mL 1.53mL 0.77mL |
15.34mL 3.07mL 1.53mL |
参考文献 |
---|